Halozyme Therapeutics Inc (NASDAQ: HALO) is 10.00% higher on its value in year-to-date trading and has touched a low of $42.01 and a high of $70.50 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The HALO stock was last observed hovering at around $58.01 in the last trading session, with the day’s loss setting it -0.2%.
Currently trading at $57.81, the stock is 5.68% and 4.74% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.11 million and changing -0.35% at the moment leaves the stock 4.33% off its SMA200. HALO registered 20.91% gain for a year compared to 6-month gain of 7.38%. The firm has a 50-day simple moving average (SMA 50) of $55.379 and a 200-day simple moving average (SMA200) of $55.39095.
The stock witnessed a 7.21% loss in the last 1 month and extending the period to 3 months gives it a -5.67%, and is 0.30% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.02% over the week and 2.37% over the month.
Halozyme Therapeutics Inc (HALO) has around 350 employees, a market worth around $7.12B and $1.08B in sales. Current P/E ratio is 15.34 and Fwd P/E is 7.85. Profit margin for the company is 44.76%. Distance from 52-week low is 37.60% and -18.01% from its 52-week high. The company has generated returns on investments over the last 12 months (24.39%).
The EPS is expected to grow by 28.47% this year
741.0 institutions hold shares in Halozyme Therapeutics Inc (HALO), with institutional investors hold 103.11% of the company’s shares. The shares outstanding are 123.17M, and float is at 121.86M with Short Float at 8.35%. Institutions hold 101.97% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 17.62 million shares valued at $922.58 million. The investor’s holdings represent 13.8613 of the HALO Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 12.88 million shares valued at $674.47 million to account for 10.1336 of the shares outstanding. The other top investors are STATE STREET CORP which holds 5.81 million shares representing 4.5739 and valued at over $304.43 million, while SNYDER CAPITAL MANAGEMENT L P holds 3.1781 of the shares totaling 4.04 million with a market value of $211.53 million.
Halozyme Therapeutics Inc (HALO) Insider Activity
The most recent transaction is an insider sale by Torley Helen, the company’s PRESIDENT AND CEO. SEC filings show that Torley Helen sold 20,000 shares of the company’s common stock on Jul 10 ’25 at a price of $57.43 per share for a total of $1.15 million. Following the sale, the insider now owns 0.73 million shares.
Halozyme Therapeutics Inc disclosed in a document filed with the SEC on Jul 09 ’25 that Torley Helen (PRESIDENT AND CEO) sold a total of 20,000 shares of the company’s common stock. The trade occurred on Jul 09 ’25 and was made at $56.43 per share for $1.13 million. Following the transaction, the insider now directly holds 0.73 million shares of the HALO stock.
Still, SEC filings show that on Jul 08 ’25, Torley Helen (PRESIDENT AND CEO) disposed off 20,000 shares at an average price of $55.51 for $1.11 million. The insider now directly holds 733,719 shares of Halozyme Therapeutics Inc (HALO).
